Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer

被引:9
|
作者
Ren, Yifan [1 ]
Song, Jialong [1 ]
Li, Xinyi [1 ]
Luo, Na [1 ]
机构
[1] Nankai Univ, Sch Med, Dept Histol, Tianjin 300071, Peoples R China
基金
中国国家自然科学基金;
关键词
cancer therapy; metastatic triple-negative breast cancer; anticancer drugs; immunotherapy; immune checkpoint blockade therapy; PD-1; PD-L1; clinical trails; CHECKPOINT BLOCKADE; ANTITUMOR IMMUNITY; 1ST-LINE TREATMENT; PLUS CHEMOTHERAPY; DOUBLE-BLIND; OPEN-LABEL; T-CELLS; ATEZOLIZUMAB; PEMBROLIZUMAB; THERAPY;
D O I
10.3390/ijms23168878
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metastatic triple-negative breast cancer (mTNBC), a highly aggressive and malignant tumor, currently lacks an effective treatment. There has been some progress in the treatment of mTNBC with programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) immunotherapy in recent years. The combination of PD-1/PD-L1 inhibitors with other therapies is a noteworthy treatment strategy. Immunotherapy in combination with chemotherapy or small-molecule inhibitors still faces many challenges. Additionally, there are some new immunotherapy targets in development. We aimed to further evaluate the effectiveness and usefulness of immunotherapy for treating mTNBC and to propose new immunotherapy strategies. This review explains the rationale and results of existing clinical trials evaluating PD-1/PD-L1 inhibitors alone or in combination for the treatment of mTNBC. For patients with aggressive tumors and poor health, PD-1/PD-L1 inhibitors, either alone or in combination with other modalities, have proven to be effective. However, more research is needed to explore more effective immunotherapy regimens that will lead to new breakthroughs in the treatment of mTNBC.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] PD-L1/PD-1 blockade in breast cancer: The immunotherapy era
    Li, Chia-Jung
    Lin, Li-Te
    Hou, Ming-Feng
    Chu, Pei-Yi
    ONCOLOGY REPORTS, 2021, 45 (01) : 5 - 12
  • [22] PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer
    Jia, Yan
    Zhang, Jie
    Shi, Yehui
    Dong, Guolei
    Guo, Xiaojing
    Tong, Zhongsheng
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [23] Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis
    Yang, Juan
    Liu, Chen
    Guo, Yaru
    Guo, Wenwen
    Wu, Xiaojin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [24] Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
    Sun, Jiangang
    Zheng, Yichao
    Mamun, M. A. A.
    Li, Xiaojing
    Chen, Xiaoping
    Gao, Yongshun
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 129
  • [25] PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer
    Zhu, Haiying
    Du, Chengyong
    Yuan, Meng
    Fu, Peifen
    He, Qiaojun
    Yang, Bo
    Cao, Ji
    DRUG DISCOVERY TODAY, 2020, 25 (09) : 1762 - 1771
  • [26] Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
    Abdin, Shifaa M.
    Zaher, Dana M.
    Arafa, El-Shaimaa A.
    Omar, Hany A.
    CANCERS, 2018, 10 (02)
  • [27] Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
    Chen, Xingyu
    Feng, Lixiang
    Huang, Yujing
    Wu, Yi
    Xie, Na
    CANCERS, 2023, 15 (01)
  • [28] PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?
    Mathias, Carolina
    Kozak, Vanessa Nascimento
    Magno, Jessica Maria
    Baal, Suelen Cristina Soares
    dos Santos, Victor Henrique Apolonio
    Ribeiro, Enilze Maria de Souza Fonseca
    Gradia, Daniela Fiori
    Castro, Mauro Antonio Alves
    de Oliveira, Jaqueline Carvalho
    CANCERS, 2023, 15 (19)
  • [29] Harmonizing PD-L1 testing in metastatic triple negative breast cancer
    Giugliano, Federica
    Antonarelli, Gabriele
    Tarantino, Paolo
    Cortes, Javier
    Rugo, Hope S.
    Curigliano, Giuseppe
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (03) : 345 - 348
  • [30] PD-1/PD-L1 and immunotherapy for pancreatic cancer
    Feng, Mengyu
    Xiong, Guangbing
    Cao, Zhe
    Yang, Gang
    Zheng, Suli
    Song, Xujun
    You, Lei
    Zheng, Lianfang
    Zhang, Taiping
    Zhao, Yupei
    CANCER LETTERS, 2017, 407 : 57 - 65